Does the media refer more to SDGR or LENZ?

In the previous week, Schrodinger and Schrodinger both had 3 articles in the media. Schrodinger's average media sentiment score of 1.15 beat LENZ Therapeutics' score of 0.90 indicating that Schrodinger is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Schrodinger 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LENZ Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LENZ or PHAR?

In the previous week, Pharming Group had 2 more articles in the media than LENZ Therapeutics. MarketBeat recorded 5 mentions for Pharming Group and 3 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 0.90 beat Pharming Group's score of 0.27 indicating that LENZ Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENZ Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LENZ or CGEM?

In the previous week, Cullinan Therapeutics had 1 more articles in the media than LENZ Therapeutics. MarketBeat recorded 4 mentions for Cullinan Therapeutics and 3 mentions for LENZ Therapeutics. Cullinan Therapeutics' average media sentiment score of 0.95 beat LENZ Therapeutics' score of 0.90 indicating that Cullinan Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LENZ Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor KURA or LENZ?

In the previous week, Kura Oncology had 8 more articles in the media than LENZ Therapeutics. MarketBeat recorded 11 mentions for Kura Oncology and 3 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 0.90 beat Kura Oncology's score of -0.67 indicating that LENZ Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative LENZ Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ABUS or LENZ?

In the previous week, LENZ Therapeutics had 1 more articles in the media than Arbutus Biopharma. MarketBeat recorded 3 mentions for LENZ Therapeutics and 2 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.28 beat LENZ Therapeutics' score of 0.90 indicating that Arbutus Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LENZ Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

LENZ Therapeutics (LENZ) Competitors

$7.44 -0.34 (-4.37%)

Closing price 04:00 PM Eastern

Extended Trading

$7.50 +0.05 (+0.74%)

As of 07:05 PM Eastern

Compare

LENZ vs. SDGR, PHAR, CGEM, KURA, and ABUS

Should you buy LENZ Therapeutics stock or one of its competitors? MarketBeat compares LENZ Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LENZ Therapeutics include Schrodinger (SDGR), Pharming Group (PHAR), Cullinan Therapeutics (CGEM), Kura Oncology (KURA), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry.

How does LENZ Therapeutics compare to Schrodinger?

Schrodinger (NASDAQ:SDGR) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

Schrodinger has a beta of 1.64, suggesting that its share price is 64% more volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market.

Schrodinger presently has a consensus target price of $20.25, indicating a potential upside of 28.16%. LENZ Therapeutics has a consensus target price of $29.80, indicating a potential upside of 300.54%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe LENZ Therapeutics is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Schrodinger and Schrodinger both had 3 articles in the media. Schrodinger's average media sentiment score of 1.15 beat LENZ Therapeutics' score of 0.90 indicating that Schrodinger is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Schrodinger	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LENZ Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LENZ Therapeutics has lower revenue, but higher earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrodinger	$255.87M	4.56	-$103.26M	-$1.41	N/A
LENZ Therapeutics	$19.09M	12.22	-$82.13M	-$3.60	N/A

79.1% of Schrodinger shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 10.1% of Schrodinger shares are held by insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Schrodinger has a net margin of -40.61% compared to LENZ Therapeutics' net margin of -519.30%. Schrodinger's return on equity of -30.85% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Schrodinger	-40.61%	-30.85%	-15.32%
LENZ Therapeutics	-519.30%	-46.82%	-43.32%

Summary

Schrodinger beats LENZ Therapeutics on 9 of the 15 factors compared between the two stocks.

How does LENZ Therapeutics compare to Pharming Group?

LENZ Therapeutics (NASDAQ:LENZ) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

LENZ Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market. Comparatively, Pharming Group has a beta of -0.04, indicating that its share price is 104% less volatile than the broader market.

54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by insiders. Comparatively, 2.1% of Pharming Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Pharming Group has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09M	12.22	-$82.13M	-$3.60	N/A
Pharming Group	$376.13M	2.46	$2.85M	$0.16	81.88

In the previous week, Pharming Group had 2 more articles in the media than LENZ Therapeutics. MarketBeat recorded 5 mentions for Pharming Group and 3 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 0.90 beat Pharming Group's score of 0.27 indicating that LENZ Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LENZ Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharming Group	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LENZ Therapeutics presently has a consensus target price of $29.80, suggesting a potential upside of 300.54%. Pharming Group has a consensus target price of $38.33, suggesting a potential upside of 192.62%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe LENZ Therapeutics is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Pharming Group has a net margin of 3.30% compared to LENZ Therapeutics' net margin of -519.30%. Pharming Group's return on equity of 4.64% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	-519.30%	-46.82%	-43.32%
Pharming Group	3.30%	4.64%	2.55%

Summary

LENZ Therapeutics and Pharming Group tied by winning 8 of the 16 factors compared between the two stocks.

How does LENZ Therapeutics compare to Cullinan Therapeutics?

LENZ Therapeutics (NASDAQ:LENZ) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

LENZ Therapeutics has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09M	12.22	-$82.13M	-$3.60	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

In the previous week, Cullinan Therapeutics had 1 more articles in the media than LENZ Therapeutics. MarketBeat recorded 4 mentions for Cullinan Therapeutics and 3 mentions for LENZ Therapeutics. Cullinan Therapeutics' average media sentiment score of 0.95 beat LENZ Therapeutics' score of 0.90 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LENZ Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LENZ Therapeutics presently has a consensus target price of $29.80, indicating a potential upside of 300.54%. Cullinan Therapeutics has a consensus target price of $30.75, indicating a potential upside of 89.70%. Given LENZ Therapeutics' higher probable upside, analysts plainly believe LENZ Therapeutics is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Cullinan Therapeutics has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -519.30%. LENZ Therapeutics' return on equity of -46.82% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	-519.30%	-46.82%	-43.32%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

LENZ Therapeutics has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market.

54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 8.3% of LENZ Therapeutics shares are owned by insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Cullinan Therapeutics beats LENZ Therapeutics on 8 of the 15 factors compared between the two stocks.

How does LENZ Therapeutics compare to Kura Oncology?

Kura Oncology (NASDAQ:KURA) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

Kura Oncology presently has a consensus target price of $25.90, suggesting a potential upside of 186.82%. LENZ Therapeutics has a consensus target price of $29.80, suggesting a potential upside of 300.54%. Given LENZ Therapeutics' higher possible upside, analysts clearly believe LENZ Therapeutics is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Kura Oncology has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market.

In the previous week, Kura Oncology had 8 more articles in the media than LENZ Therapeutics. MarketBeat recorded 11 mentions for Kura Oncology and 3 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 0.90 beat Kura Oncology's score of -0.67 indicating that LENZ Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
LENZ Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kura Oncology has a net margin of -411.19% compared to LENZ Therapeutics' net margin of -519.30%. LENZ Therapeutics' return on equity of -46.82% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-411.19%	-141.95%	-43.28%
LENZ Therapeutics	-519.30%	-46.82%	-43.32%

54.3% of LENZ Therapeutics shares are held by institutional investors. 7.6% of Kura Oncology shares are held by insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

LENZ Therapeutics has lower revenue, but higher earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than LENZ Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	11.88	-$278.67M	-$3.35	N/A
LENZ Therapeutics	$19.09M	12.22	-$82.13M	-$3.60	N/A

Summary

LENZ Therapeutics beats Kura Oncology on 9 of the 16 factors compared between the two stocks.

How does LENZ Therapeutics compare to Arbutus Biopharma?

Arbutus Biopharma (NASDAQ:ABUS) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

In the previous week, LENZ Therapeutics had 1 more articles in the media than Arbutus Biopharma. MarketBeat recorded 3 mentions for LENZ Therapeutics and 2 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.28 beat LENZ Therapeutics' score of 0.90 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LENZ Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arbutus Biopharma has a net margin of 83.95% compared to LENZ Therapeutics' net margin of -519.30%. Arbutus Biopharma's return on equity of 129.32% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	83.95%	129.32%	112.24%
LENZ Therapeutics	-519.30%	-46.82%	-43.32%

Arbutus Biopharma currently has a consensus target price of $5.00, indicating a potential upside of 11.61%. LENZ Therapeutics has a consensus target price of $29.80, indicating a potential upside of 300.54%. Given LENZ Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe LENZ Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 19.9% of Arbutus Biopharma shares are held by insiders. Comparatively, 8.3% of LENZ Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Arbutus Biopharma has higher earnings, but lower revenue than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	62.85	-$33.50M	$0.83	5.40
LENZ Therapeutics	$19.09M	12.22	-$82.13M	-$3.60	N/A

Arbutus Biopharma has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

Summary

Arbutus Biopharma beats LENZ Therapeutics on 10 of the 16 factors compared between the two stocks.

Get LENZ Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LENZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LENZ vs. The Competition

Export

Metric	LENZ Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$233.24M	$3.32B	$6.31B	$12.59B
Dividend Yield	N/A	2.28%	2.68%	5.22%
P/E Ratio	-2.07	18.07	21.13	26.63
Price / Sales	12.22	326.58	546.66	114.76
Price / Cash	N/A	54.19	27.44	37.60
Price / Book	0.82	6.84	9.95	6.88
Net Income	-$82.13M	$24.15M	$3.56B	$336.73M
7 Day Performance	-1.46%	1.93%	2.12%	4.19%
1 Month Performance	N/A	N/A	N/A	-0.08%
1 Year Performance	-74.60%	62.98%	36.32%	40.26%

LENZ Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LENZ LENZ Therapeutics	2.7952 of 5 stars	$7.44 -4.4%	$29.80 +300.5%	-73.4%	$233.24M	$19.09M	N/A	110
SDGR Schrodinger	3.2621 of 5 stars	$13.15 -1.1%	$20.25 +54.0%	-29.7%	$970.73M	$255.87M	N/A	790
PHAR Pharming Group	3.7989 of 5 stars	$13.62 +8.1%	$38.33 +181.4%	+19.2%	$961.84M	$376.13M	85.13	280	Positive News
CGEM Cullinan Therapeutics	3.5164 of 5 stars	$15.46 +11.7%	$30.75 +98.9%	+89.8%	$950.17M	N/A	N/A	30
KURA Kura Oncology	2.2244 of 5 stars	$10.41 -7.5%	$26.38 +153.4%	+79.6%	$924.10M	$67.48M	N/A	130

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LENZ) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LENZ Therapeutics (LENZ) Competitors

LENZ vs. SDGR, PHAR, CGEM, KURA, and ABUS

How does LENZ Therapeutics compare to Schrodinger?

Summary

How does LENZ Therapeutics compare to Pharming Group?

Summary

How does LENZ Therapeutics compare to Cullinan Therapeutics?

Summary

How does LENZ Therapeutics compare to Kura Oncology?

Summary

How does LENZ Therapeutics compare to Arbutus Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LENZ vs. The Competition

LENZ Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LENZ Therapeutics (LENZ) Competitors

LENZ vs. SDGR, PHAR, CGEM, KURA, and ABUS

How does LENZ Therapeutics compare to Schrodinger?

Which has more risk & volatility, SDGR or LENZ?

Do analysts prefer SDGR or LENZ?

Does the media refer more to SDGR or LENZ?

Which has stronger earnings & valuation, SDGR or LENZ?

Do insiders and institutionals believe in SDGR or LENZ?

Is SDGR or LENZ more profitable?

Summary

How does LENZ Therapeutics compare to Pharming Group?

Which has more volatility and risk, LENZ or PHAR?

Do institutionals and insiders have more ownership in LENZ or PHAR?

Which has stronger valuation and earnings, LENZ or PHAR?

Does the media favor LENZ or PHAR?

Do analysts prefer LENZ or PHAR?

Is LENZ or PHAR more profitable?

Summary

How does LENZ Therapeutics compare to Cullinan Therapeutics?

Which has stronger valuation & earnings, LENZ or CGEM?

Does the media prefer LENZ or CGEM?

Do analysts recommend LENZ or CGEM?

Is LENZ or CGEM more profitable?

Which has more risk and volatility, LENZ or CGEM?

Do institutionals & insiders have more ownership in LENZ or CGEM?

Summary

How does LENZ Therapeutics compare to Kura Oncology?

Do analysts prefer KURA or LENZ?

Which has more volatility & risk, KURA or LENZ?

Does the media favor KURA or LENZ?

Is KURA or LENZ more profitable?

Do insiders & institutionals have more ownership in KURA or LENZ?

Which has higher valuation & earnings, KURA or LENZ?

Summary

How does LENZ Therapeutics compare to Arbutus Biopharma?

Does the media refer more to ABUS or LENZ?

Is ABUS or LENZ more profitable?

Do analysts recommend ABUS or LENZ?

Do insiders and institutionals believe in ABUS or LENZ?

Which has stronger valuation and earnings, ABUS or LENZ?

Which has more volatility & risk, ABUS or LENZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LENZ vs. The Competition

LENZ Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools